Construction of a diabody (small recombinant bispecific antibody) using a refolding system

被引:30
作者
Takemura, S
Asano, R
Tsumoto, K
Ebara, S
Sakurai, N
Katayose, Y
Kodama, H
Yoshida, H
Suzuki, M
Imai, K
Matsuno, S
Kudo, T
Kumagai, I [1 ]
机构
[1] Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 980, Japan
[2] Tohoku Univ, Sch Med, Dept Surg 1, Sendai, Miyagi 980, Japan
[3] Tohoku Univ, Inst Dev Aging & Canc, Cell Resource Ctr Biomed Res, Sendai, Miyagi 980, Japan
[4] Sapporo Med Univ, Sch Med, Dept Internal Med, Sapporo, Hokkaido, Japan
来源
PROTEIN ENGINEERING | 2000年 / 13卷 / 08期
关键词
bispecific antibody; diabody; diabody-T-LAK cell; MUC1; refolding system;
D O I
10.1093/protein/13.8.583
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diabodies are the recombinant bispecific antibodies (BsAbs), constructed from heterogeneous single-chain antibodies. Usually, diabodies have been prepared from bacterial periplasmic fraction using a co-expression vector (i.e. genes encoding two chains were tandemly located under the same promoter), Some diabodies, however, cannot be expressed as a soluble material owing to inclusion body formation, which limits the utilization of diabodies in various fields. Here we report an improved method for the construction of diabodies using a refolding system. As a model, a bispecific diabody binding to adenocarcinoma-associated antigen MUC1 and to CD3 on T cells was studied. One chain consisted of a VH specific for MUC1 linked to a VL specific for CD3 with a short polypeptide linker (GGGGS), The second was composed of ar VL specific for MUC1 linked to a VH specific for CD3, The two hetero scFvs were independently obtained from intracellular insoluble fractions of Escherichia coli, purified, mixed stoichiometrically (at an equivalent molar ratio of 1:1) and refolded, The refolded two hetero scFv has a hetero-dimeric structure, with complete specificity for both target cells [i.e. MUC1 positive cells and CD3 positive lymphokine-activated killer cells with a T cell phenotype (T-LAK)]. Evaluation of the in vitro efficacy of T-LAK with the diabody by growth inhibition assay of cancer cells demonstrated maximum growth inhibition of cancer cells to reach similar to 98% at an effector:target ratio (E:T ratio) of 10, almost identical with that with anti-MUC1Xanti-CD3 chemically synthesized BsAbs (c-BsAbs), This is the first report of the construction of a diabody using a refolding system.
引用
收藏
页码:583 / 588
页数:6
相关论文
共 37 条
  • [1] Arakawa F, 1996, J BIOCHEM, V120, P657
  • [2] A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors
    Arndt, MAE
    Krauss, J
    Kipriyanov, SM
    Pfreundschuh, M
    Little, M
    [J]. BLOOD, 1999, 94 (08) : 2562 - 2568
  • [3] Functional construction of the anti-mucin core protein (MUC1) antibody MUSE11 variable regions in a bacterial expression system
    Asano, R
    Takemura, S
    Tsumoto, K
    Sakurai, N
    Teramae, A
    Ebara, S
    Katayose, Y
    Shinoda, M
    Suzuki, M
    Imai, K
    Matsuno, S
    Kudo, T
    Kumagai, I
    [J]. JOURNAL OF BIOCHEMISTRY, 2000, 127 (04) : 673 - 679
  • [4] BAN T, 1989, CANCER RES, V49, P7141
  • [5] SINGLE-CHAIN ANTIGEN-BINDING PROTEINS
    BIRD, RE
    HARDMAN, KD
    JACOBSON, JW
    JOHNSON, S
    KAUFMAN, BM
    LEE, SM
    LEE, T
    POPE, SH
    RIORDAN, GS
    WHITLOW, M
    [J]. SCIENCE, 1988, 242 (4877) : 423 - 426
  • [6] BOHLEN H, 1993, CANCER RES, V53, P4310
  • [7] Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library
    deKruif, J
    Logtenberg, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (13) : 7630 - 7634
  • [8] GRUBER M, 1994, J IMMUNOL, V152, P5368
  • [9] Helfrich W, 1998, INT J CANCER, V76, P232, DOI 10.1002/(SICI)1097-0215(19980413)76:2<232::AID-IJC11>3.3.CO
  • [10] 2-N